Price: quote on request. Your total cost is quoted in writing per case.
We reply within one business dayGet my quote

Thyroid eye disease (Graves eye disease): US-approved treatments and how Gulf families can access them

Creator: Reserve Meds
Published: 2026-10-17

A plain guide for families in the Gulf, checked against US FDA labels, Gulf drug registers and published medical research.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026.

Thyroid eye disease: the short answer

For thyroid eye disease, the US FDA has approved two medicines covered on this page, each for a specific group of patients: Tepezza and Lumvoa. Where a medicine is not registered in your country, the treating hospital can ask the national regulator for permission to import it for one named patient. Reserve Meds is a digital health company that helps families and hospitals with that process. We do not diagnose or prescribe.

US FDA-approved medicines on this page: Tepezza and Lumvoa.
Gulf registration (checked 17 October 2026): see each medicine below.
Legal route: Local supply where listed; otherwise a named-patient import request filed by the treating hospital.
Price: Quote on request.

What is thyroid eye disease?

Thyroid eye disease is an autoimmune inflammatory disorder of the soft tissues in the bony socket around the eye. It is also known as Graves eye disease. It most often occurs with an overactive thyroid, but it can also occur with normal or low thyroid function.^[1]

The most common sign is eyelid retraction. Others include bulging eyes, double vision, eyelid swelling, redness, tearing and, in severe cases, vision loss from pressure on the optic nerve. The active phase lasts about one year in nonsmokers and can last longer in smokers. Quitting smoking is strongly encouraged.^[1]

Thyroid eye disease in the Gulf

We did not find published Gulf population figures for thyroid eye disease that we could verify, so we do not give any. Neither Tepezza nor Lumvoa was part of the Gulf register check we ran on 17 October 2026, so we confirm their status for your country when you ask.

Both medicines are given as a course of intravenous infusions every three weeks, so families who travel for treatment need to plan for several visits, or for a local hospital that can give the infusions once the medicine is supplied.^{[2, 3]}

US FDA-approved medicines for thyroid eye disease

Each medicine below is approved in the US for a specific group of patients. The wording follows the current US label. Your specialist decides whether any of them is right for the patient.

Tepezza (teprotumumab-trbw)
FDA-approved for thyroid eye disease, whatever its activity or duration. It is given as eight intravenous infusions, every 3 weeks.^[2]
Current US label version: 24 June 2026. Gulf registers: Not part of our 17 October 2026 Gulf register check. We confirm the status for your country when you ask.
Country guides: Saudi Arabia, UAE, Egypt, India, Pakistan
Lumvoa (veligrotug)
FDA-approved for thyroid eye disease, whatever its activity or duration. It is given as five intravenous infusions, every 3 weeks.^{[4, 3]}
US FDA approval: 26 June 2026. Gulf registers: Not part of our 17 October 2026 Gulf register check. We confirm the status for your country when you ask.

How families in the Gulf can access these medicines

If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital pharmacy confirms.^{[5, 6]} Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital pharmacy.

Who does what

Your treating specialist decides whether a medicine is right for the patient and writes the letter.
The hospital checks local supply, files any import request, and gives the treatment safely.
The national regulator decides whether to approve the import of a medicine that is not registered.
The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.

Documents you will usually need

A letter from the treating specialist with the diagnosis, past treatments and why this medicine is being considered
Reports that confirm the diagnosis, such as genetic, pathology or laboratory results, translated into English where needed
Recent clinic notes and a list of current medicines
For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
Proof of the US FDA approval and the US prescribing information (we can supply these)

We give you a written timeline estimate once we see the hospital file. The regulator, the treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.

Ask us about treatment for thyroid eye disease

Tell us the medicine, the country, and how to reach you. We reply within one business day. On WhatsApp we usually reply the same day.

Message us on WhatsApp Already have a case? Sign in

Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

Frequently asked questions

Is there an FDA-approved treatment for thyroid eye disease?

Yes. The medicines on this page have US FDA approval for specific groups of patients: Tepezza and Lumvoa. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.

Is Tepezza available in Saudi Arabia or the UAE?

Not part of our 17 October 2026 Gulf register check. We confirm the status for your country when you ask. A listing in Abu Dhabi does not show federal UAE status, which we could not verify.

How can a family in the Gulf get Tepezza?

Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital pharmacy.

How much does treatment cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

Does Reserve Meds diagnose or prescribe?

No. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We do not diagnose, prescribe or decide what a regulator approves. Your specialist and hospital make the medical decisions.

How many infusions are needed?

The US labels describe eight infusions every 3 weeks for Tepezza and five infusions every 3 weeks for Lumvoa. Your eye and thyroid specialists decide which, if either, is right for you.

Sources for the last answer: ^{[2, 3]}

Sources

Checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital pharmacy confirms the current position before filing.

This page is general health information, not medical advice. It does not replace a consultation with your doctor.